Esophageal cancer
Conditions
Interventions
Docetaxel 70mg/m2 day1
Cisplatin 70mg/m2 day1
Fluorouracil 750mg/m2/day days1-5
Pegfilgrastim 3.6mg day3
3 courses every 3 weeks
Sponsors
Maeda Osamu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.ECOG PS 0-1 2.Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma or basal cell carcinoma. 3. Any of the following based on TNM classification (UICC-TNM 7 th edition) 1) cStage IB 2) cStage II 3) cStage III Infiltration into the trachea at the cervical /cervical chest boundary (T4) is eligible. Excluding other T4. So-called borderline-resectable T4 disease, not clearly diagnosed as T4, is eligible. 4) cStage IV with supraclavicular lymph node metastasis and without other distant metastasis. 4. Adequate organ function.
Exclusion criteria
Exclusion criteria: 1) Clear T4 other than invasion of cervical / cervical gastrointestinal tract esophageal cancer 2) Distant metastasis to other than supraclavicular lymph nodes. 3) Esophagogastric junction lesion of which main lesion is located in the stomach rather than the esophagus. 4) Judged not to be eligible by the researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of febrile neutropenia | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of Grade 3 or higher neutropenia, curative resection rate, response rate of preoperative treatment, histopathological response rate, histopathological complete response rate, rate of adverse events during preoperative therapy, rate of incidence of perioperative complications, late complication rate, serious adverse event rate, progression-free survival, and overall survival | — |
Contacts
Public ContactOsamu Maeda
Nagoya University
Outcome results
None listed